farmaci d'urgenza

8/12/2019 Farmaci d'Urgenza

1/32

"""#$%&'()*%+,+%$,+%&%-.#%/

Farmaci durgenza

"#$%%&'()* +&),& -$))&..&

%-0(1$%&'()*%+,+%$,+%&%-.#%/


2/32

234564728

9+',-.:%-. 3('.+',-.:%-. ;(?59@>A4BB93528

9/,-(:(:( C,/(='(:(:( 7'(='.-(:(:( A.69;2B96;2B28

9/'(=%-. 2D(=',-.:%-.

935259BE2B96;2B28 7'(=.0,-(-, 9$%(+.'(-, F(/.:(:( ;%)(DD%-.

B.@9359G432F528

;%:/%.H,$ I,'.=.$%:

;2J6?52B2 ? 32564;?62I9528

K*'(D,$%+, 3%/'():%&,'%-. 3%/'(='*DD%./(


3/32

9A5628

9$%-(0%::%-. F($./(D/./%-.

?=.'%-. F(+%&. 5'($F9 L >:(&&( F,-( 9/'%.:,

5FI L 5.&N%&.'+%. F(='.I,-/'%&(:.',

57FI L V(:00 7.'W%-D(- VN%/,

FFF L F%&W F%-*D FX-+'($,

7C L 7.&,$.W,'

2C9 L 2-0.'/( C%(&.'+%&( 9&*/(

>7B4 L >'(-&(=-,*$(=./%. B'(-%&. 4D/'*//%O.

?79 L ?+,$. 7(:$(-.', 9&*/(

?7 L ?$


4/32

!"#$%!&'%!

Y$)ZY$: [9+',-.:%-.\

Y8YQQQ

3'(,8&.,*',89'',D/( &.'+%.&( +. KI ( 5IR .D%D/(:%.R 7?9 9-.0%:.DD%

;(D.))%(8 O,+% /.


5/32

>5?"@@3 ">016"A36"

,-./-0.1-2/! 3.,4-252602/.,!

78 # 98! #$ %&'& ()*) +$ ,- ./)01 2,- 0+0$) (+ 3456

*)+ ! #$ %&'& 7 0+0$+ 7$8%9:+ 2);:+ ,+:?8+6

.:(:$%;(+ %

5!.

! #$ %&'& 7**%:7 *)..+@+$%

*)+ ! #$ %&'& 7 0+0$+ 7$8%9:+ 2);:+ ,+:?8+6

./.9-6.+:+.8979% +: 07.) (+ 7$8%97A+):+ (%$$% '+% 7%9%%B

*)$>):79+ ) 0+90)$78)9+% 7 9+.0/+) *%9 $7 '+876

-/7,.0=%(+) (%$$7 0).0+7 +: 7:8%9)$78%97$%2*+C .+0?97B :): 9+0/+%(% 700%..+ '%:).+6

.*>;$( ?@@ )AB C@D? ); *( "; E'E@@@F

G+)H(I( J EK +II( ?@@ )AB C@D? ); *( "; E'E@@@F

G+)H(I( LMEK +II( N@@ )AB C@DN ); *( "; E'E@@@F

G+)H(I( O L +II( E?@ )AB C@DE? ); *( "; E'E@@@F

,(P#$#Q# *%P% ? )(I>$( :# I% )(B;(%Q+)#I$%

!/428!/. D7 #$ !E!FFF 2!>; +: ! >$6 '7 GHI53H (+$?+87

2 RISCHIO di effetti collaterali se diagnosi sbagliata6

5%Q$+Q# E "; *+ E )B + E@ ); C:%;>R(%I# E'E@@@@F

.*>;$( ?@ )AB C@D? ); *( :%;>R(%I# E'E@@@@F

G+)H(I( E )ABSTB C@D@E );STB *( :%;>R(%I# E'E@@@@F


6/32

%)#!"#$%!&'%!

]$)ZY$: [3('.+',-.:%-. /.'/'./(\

3'(,8&.,*',8

FN(&W &.'+%(),-( FN(&W D,//%&(955?3^243?8 -(- +% ='%$. :%-,.R %-+%&./( %- .DD(&%.H%(-, .

:%M*%+% , %-(/'(=% [+(


7/32

>5?"@@3 650">016"A36"

4%:+BB(% (I(R(+;#' @D?ME )ABS)(I

.BB(>:$+)#I$(' E )ABS)(I %BI( ?M10#+:) 7 9+.*).87

%>)(+:7>+07

956 +3905@59935A"B501

E"; (I K?@AA *( 0;K>+:6 L MB= V );SW *+ (I"%I*#Q#

4%:+BB(% (I(R(+;# @D?ME )ABS)(I XMU );SW

5#Q %BI( (IAQ#)#I$% *( E )ABS)(I 8 ml/h

4%:+BB(% )+Y N@ )ABS)(I KK? );SW

956 POMPA DINFUSIONE

E"; (I ?@AA *( 0;K>+:6 L FBNN V );SW *+ (I"%I*#Q#

4%:+BB(% (I(R(+;# @D?ME )ABS)(I @DNM@DL );SW5#Q %BI( (IAQ#)#I$% *( E )ABS)(I 0,6 ml/h

4%:+BB(% )+Y N@ )ABS)(I K@ );SW


8/32

")*+,!-'%!

]UQ$)Z]Q$: [;(


9/32

>5?"@@3 >5/CB"+36"

4%:+BB(% (I(R(+;#' KD?)ABSTBS)(I

Aggiustamenti:2,5mcg/Kg/min ogni 10M15#+:) 7 9+.*).87

%>)(+:7>+07

4%:# )+::()+' !=>0;KO;K>+: 2PF >0;KO;K>+: +: *7A+%:8+

@%87@$)0078+6

.77!/1-2/!' :%:P#I*#Q# BQ+*>+;)#I$#

956 +3905@59935A"B501

E"; (I K?@AA *( 0;K>+:6 L *%.) 2O;6 L FBFNV );SW *+ (I"%I*#Q#

)ABSTBS)(I KD? ? E@

?@ TB ZD? );SW E? );SW N@ );SW

L@ TB [ );SW EU );SW NL );SW

Z@ TB E@D? );SW KE );SW XK );SW

[@ TB END? );SW KZ );SW ?X );SW

956 POMPA DINFUSIONE

E"; (I ?@AA *( 0;K>+:6 L *%.) 2O;6 L FBF!PV );SW *+ (I"%I*#Q#

)ABSTBS)(I KD? ? E@

?@ TB ED? );SW N );SW L );SW

L@ TB EDU );SW NDL );SW ZDK );SW

Z@ TB KDE );SW XDK );SW UDX );SW

[@ TB KDZ );SW ?DX );SW E@DU );SW


10/32

").!-'%!

]QQ$)ZU$: [6,O%O.-\

3'(,8&.,*',8

Q7..) ().7;;+)8 *%P+)(I#QB(A+ C\+:%*(;+$+R(%I#Fgittata cardiaca con compromissione renale (oliguria)J).7;;+) >%(+) ) %$%'78)8-+*Q#I#QB(A% C(I%$Q%P%F ed M

+*Q#I#QB(A% C\+:%A%:$Q(R(%I#F

;(D,8 O,+% /.


11/32

!,#).'%!

Y$)ZY$: [9/'(=%-. D(:0./(\

3'(,8&.,*',8

>'.+%&.'+%, , >9I 2=(/,-D%(-, +. %=,'/(-( O.).:,

;(D,8 1mg ripetibile a 5;(D, $._' @D@X)BSTB CA(QA+ N)BF

!""#$$% ' 2

! #$$% )+Y' KMX45

;)$8&


12/32

'/).#$%!&'%!

QR] $)ZY$: [2D(=',-.:%-. &:('%+'./(\

3'(,8&.,*',8

>'.+%&.'+%, ,$(+%-.$%&.$,-/,D%)-%0%&./%O,R ',D%D/,-/% .::. ./'(=%-. [G;%AAW( :%$$%W(:(+I(\

5('D%(-, +% =*-/.

;(D,8 O,+% /.+:6 L NV );SW *+ (I"%I*#Q#

)ABS)(I );SW )ABS)(I );SWE L EK ZK

K EK E? [@

? N@ EU E@U

E@ L@ K@ EK@


13/32

.#).!0$%)%$

eQ$)Z]Q$: [6X/$(-('$\

3'(,8&.,*',8

5FI [K:*//,' 9/'%.:,R K9R 57FI\ 9'%/$%, %- =',D,-H. +% V7V

;(D,8 =$(, :&K$##&!""#$$% ' 1

!""#$$% )+Y' 10 20MN@

;)$8&7:8%:+>%:8)

7 !P= >$K/

2P )9%6

9*':)*,'(,8&.,*',8

2-D*00%&%,-H. &.'+%.&. , DN(&W &.'+%(),-(R 79cYQQ [%-( @\FFFR >9I +% 22 , 222R >>F- , >:(&&N% 0.D&%&(:.'%R KBcUQ

? ./( ./%. '.O, C%.D/,-%. >7B4


14/32

!-')"!#)%$

YUQ$)Zf$: [B('+.'(-,\

3'(,8&.,*',8

5FI [K:*//,' 9/'%.:,R K9R 57FI\R 5I6.::,-/.$,-/( +,::. K',M*,-H. I,-/'%&(:.', %- &('D( +%

0:*//,' ( K9

7'(0%:.DD% +% ',&%+%O, +% .'%/$%, O,-/'%&(:.'%

;(D,8 =$(, :&K$##&!""#$$% ' 10

!""#$$% )+Y' N@ML@

;)$8&


15/32

/),!&)&)

gQ$)Zg$: [6X/$(*%&DD,*7 ENMIDJSD in 10

;$%* TSDU 6


16/32

"'1)//'%!

QRU$)Z]$: [A.-(_%-\

3'(,8&.,*',8

della Freq V,-/'%&(:.', -,::, /.&N%.'%/$%, ./'%.:% %-=',D,-H. +% D&($=,-D( &.'+%.&(

;(D,8 =$(, :&K$##&!""#$$% ' ?M10

!""#$$% )+Y' KW

9*':)*,'(,8&.,*',8

V7V ['%D&N%( +% +,),-,'.H%(-, +% *-. K9 %- KI\ FFFR >F9R >9I +% )'.+( ,:,O./(

;)$8&


17/32

!,$%)&)&)

U$)ZYQ$: [5,-('$%-\

3'(,8&.,*',8

%D&N,$%. $%(&.'+%&. ,+ 2C9 [%- =.H#,$(+%-.$%&.$,-/,D/.9I +% 22 , 222 )'.+(R KB c UQ >7B4R 9D$.

;)$8&


18/32

-$,).#)&)&)

U$)ZU$: [F,:(W,-\

3'(,8&.,*',8

2C9 , %D&N,$%. $%(&.'+%&.

5.&N%.'%/$%, I,-/'%&(:.'% , F(='.O,-/'%&(:.'% 2=,'/,-D%(-, .'/,'%(D. %- =',D,-H. +% +%DD,H%(-, .('/%&.

;(D,8 =$(, :&K$##&!""#$$% ' 20

!""#$$% )+Y' K@5MUW

9*':)*,'(,8&.,*',8

2-D*00%&%,-H. &.'+%.&. , DN(&W &.'%(),-( [79F c YQQ\ FFFR >9I +% 22 , 222 )'.+(R KB c UQ >7B4R 9D$.

;)$8&


19/32

.#).#!%)&)&)

U$)ZU$: [2-+,'.:\

3'(,8&.,*',8

2C9 , %D&N,$%. $%(&.'+%&.

5.&N%.'%/$%, I,-/'%&(:.'% , F(='.O,-/'%&(:.'% 2=,'/,-D%(-, .'/,'%(D. %- =',D,-H. +% +%DD,H%(-, .('/%&.

;(D,8 =$(, :&K$##&!""#$$% ' ())#*(+$%

!""#$$% )+Y' E5

9*':)*,'(,8&.,*',8


;)$8&


20/32

&!*$,!&)&)

YQQ$)Z]Q$: [5'.-+./,\

3'(,8&.,*',8

?$,'),-H, %=,'/,-D%O, 2=,'/,-D%(-, .'/,'%(D. %- =',D,-H. +% +%DD,H%(-, .('/%&.

;(D,8 =$(, :&K$##&!""#$$% ' KM5

!""#$$% )+Y' E?2MXW

9*':)*,'(,8&.,*',8


;)$8&;K>$6 7 ,F$K/


21/32

"'&,'!2$-

UQ$)ZU$: [9:/%.H,$R

;%:H,-,R 5%:+%,$\

3'(,8&.,*',8

.-)%-. %-D/.


22/32

3$#!.!-'&

U$)Z]$: [2D(=/%-\

3'(,8&.,*',8

.-)%-. %-D/.


23/32

0+#)/$-'"$

]Q$)ZU$:d ]UQ$)Z]U$: [A.D%_\

3'(,8&.,*',8

?79R ?$,'),-H, %=,'/,-D%O, 2-D*00%&%,-H. ',-.:,R %=,'`

;(D,8 =$(, :&K$##&!""#$$% '

'7.)(+$787A+):% '%:).7E5(+?9%8+0)E20!""#$$% )+Y' XMLW

9*':)*,'(,8&.,*',8

2=(/,-D%(-,R %=(O(:,$%.9-*'%.

;)$8&


24/32

%',#)1&'4$#'%!

U$)ZYRU$: [I,-%/'%-R 3%/'(D('0;K>$6

I8DJSDJI,' HNE HNGM E G T+"YU

X@ TB X );SW E@ );SW X@ );SW U@ );SW

?@ TB ? );SW EKD? );SW ?@ );SW E@@ );SW

L@ TB L );SW E? );SW L@ );SW EK@ );SW

Z@ TB Z );SW EZD? );SW Z@ );SW EX@ );SW

U@ TB U );SW K@ );SW U@ );SW EL@ );SW

[@ TB [ );SW KKD? );SW [@ );SW EU@ );SW

"6@36" E@);SWW ?M10ml/h ogni 5+: @7.% 7 5X % ()$)9%

1;" EZD? );SW W EZD?ml/h ogni 5+: @7.% 7 5X %(+.*:%7


25/32

%',#).#+//'!,)

YQQ$)ZU$: [F(+%( -%/'(='*DD%./(\

3'(,8&.,*',8

?$,'),-H, %=,'/,-D%O, ;%DD,&.H%(-, .('/%&.

F&($=,-D( &.'+%.&( &(- ?79 , 79 .:/.

;(D,8 =$(, :&K$##&!""#$$% ' ())#:*(+$%

!""#$$% )+Y' ?E@

9*':)*,'(,8&.,*',8

B(.'/.H%(-, .('/%&. 9/'(0%. (//%&. +% A,0;K>$6

I8DJSDJI,' E G M EH

X@ TB L );SW EK );SW N@ );SW L@ );SW

L@ TB [ );SW EU );SW X? );SW [@ );SW

U@ TB EK );SW KX );SW L@ );SW EK@ );SW

[@ TB EN );SW KZ );SW LZ );SW EN? );SW

;*%%,K,#$ ,':*%%,8&.,*'$ (& B,*8,&'&:,


26/32

!-'%)0'&&'%!

]gQ$)ZYQ$: [5,0.$%-R 9$%-($.:\

3'(,8&.,*',8

9D$.


27/32

/)-!,)/,!,'%!

]UQ$&)f$)Z]$: [F/%:.$%-\

]$)Z]$: [C(+*D/./%-.\

3'(,8&.,*',8

?$(''.)%, .&*/, ).D/'%&N, ( +*(+,-.:% [*:&,',R O.'%&%\

;(D,8 O,+% /.


28/32

$.!#'%! /)"'4!

]UQ$)ZU$: [Y$: L UQQQ J2\

3'(,8&.,*',8 ?$58 F(:0./( +% ='(/.$%-. [MI# E[ W$) E I# (, $W&),'&\

9*':)*,'(,8&.,*',8

?$(''.)%. %- .//( G'.O, /'($$K/6

0,W$:,.\

&;BB

OX@ N@@@ =- @ ]K LW

X@MX[ @ @ ]E LW

?@MZ? @ @ /#::>I+ EKW

ZLMU? @ @ ME EKW

ULME@@ @ N@ MK LW

E@EME?@ @ L@ MN LW

JE?@ @ L@ ML LW


29/32

,#)-*)&','4'

3'(,8&.,*',8

2-0.'/( $%(&.'+%&( .&*/( F5?C2 ?$


30/32

*nellictus ischemico dovrebbe essere eseguita solo da

*%9.):7$% .*%0+7$+AA78) % *9%#%9+@+$>%:8% +: ?:7 .89)1% ?:+8

9*':)*,'(,8&.,*', nellictus ischemico8

?/P ljQ ( c Yj .--% F/('%. +% %&/*D , +%.


31/32

.37-6b

2PF>;KPF>$ )**?9% =F>;K=F>$6

E possibile diluire ulteriormente in Soluzione Fisiologica

-0. ;KO;

-0. ;KO;!)H%;(+ 5%;)%I+Q#

G%;% E@ )B

-I">:(%I# [@ )B (I EK@ )(I

.77!/1-2/!' Per la breve emivita (5) accompagnare la

.)>>+:+.897A+):% 7( H*79+:7 .)(+07 *%9 MP/-A$>: (:AW#)(A%

FB] >;KO; 2>7L ]F >;6

G%;% E@c *#;;+ *%:#

-I">:(%I# [@c *#;;+ *%:# (I L@ )(I

.77!/1-2/!' H'+879% 70+() 70%8+$.7$+0+$+0) ) %*79+:7 .)(+07

:%$$% *9+>% PY/ ()*) $7 89)>@)$+.+


32/32

/,K#,*D)&V,&7

V('W%-) G'(*= (0 /N, 6,D*D&%/./%(- B(*-&%: [J`\# 1I$)D$'8] :)$&:I$':*V &'&WR]#&8:,8 )$&8:,*'%\ @R 7,'W%-D G;#1

farmaci d'urgenza

Documents